The honest answer
The inflammation-signalling piece.
Short answer
KPV is a short tripeptide studied in preclinical research for inflammation signalling. In BPC Matrix it covers that part of the repair picture alongside the BPC-157 base. Studied, not proven; individual results vary.
Repair isn't only building — it's also settling the inflammation around the damage. KPV has been studied in that context.
Adding KPV to the 157 base means the blend addresses inflammation signalling, not just blood supply. See the full blend.
Straight answers
It has been studied for inflammation signalling. Nothing here is a medical claim — individual results vary and it is physician-supervised.
No — it is not an FDA-approved drug.